alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest studies

Every summary in our library, newest first, as a dated timeline.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 7,126–7,150 of 27,380 studies, newest first · page 286 of 1096.

December 2023 8

  1. 2023-12-01

    Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease

    ✓ Peer-reviewed Brain scans and imaging JAMA neurology

    Key finding: Data from 3960 MRI sessions among 1141 participants were included: 252 pathogenic variant carriers from DIAN (mean [SD] age, 38.4 [11.2] years; 137 [54%] female), 571 older adults from ADNI (mean [SD] age, 72.8 [7.3] years; 274 [48%] female), and 318 older adults from HABS (mean [SD] age, 72.4 [7.6] years; 194 [61%] female). +2 more findings

    Full summary, score breakdown and related studies → Original source

  2. 2023-12-01

    Associations of socioeconomic status and healthy lifestyle with incident early-onset and late-onset dementia: a prospective cohort study

    ✓ Peer-reviewed Prevention and risk The lancet. Healthy longevity

    Key finding: After adjusting for various risk factors, participants with low socioeconomic status (vs high) had increased risk for early-onset dementia (3·38, 2·61-4·37), and overall lifestyle mediated 3·2% (1·8-5·7) of the association. +3 more findings

    Full summary, score breakdown and related studies → Original source

  3. 2023-12-01

    Efficacy and Safety of Cilostazol in Mild Cognitive Impairment: A Randomized Clinical Trial

    ✓ Peer-reviewed Treatments JAMA network open

    Key finding: The full analysis set included 159 patients (66 [41.5%] male; mean [SD] age, 75.6 [5.2] years) who received placebo or cilostazol at least once. +1 more finding

    Full summary, score breakdown and related studies → Original source

  4. 2023-12-01

    Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial

    ✓ Peer-reviewed Treatments JAMA neurology

    Key finding: In this randomized clinical trial, BIIB080 reduced tau biomarkers, including CSF t-tau, CSF p-tau181, and tau PET, which is associated with cognitive decline, in participants with mild AD. +4 more findings

    Full summary, score breakdown and related studies → Original source

  5. 2023-12-01

    Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial

    ✓ Peer-reviewed Treatments JAMA neurology

    Key finding: In this study, patients with Alzheimer dementia who took brexpiprazole, 2 or 3 mg, showed a statistically significant improvement vs placebo in agitation over 12 weeks. +2 more findings

    Full summary, score breakdown and related studies → Original source

  6. 2023-12-01

    ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels

    ✓ Peer-reviewed Biomarkers JAMA neurology

    Key finding: The mean (SD) age was 73.9 (7.35) years among the 237 ADNI participants and 70.2 (9.7) years among the 130 Avid-A05 participants. +1 more finding

    Full summary, score breakdown and related studies → Original source

  7. 2023-12-01

    APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry

    ✓ Peer-reviewed Genetics JAMA Neurology

    Key finding: Among 68 756 unique individuals, analyses included 21 852 East Asian (demographic data not available), 5738 Hispanic (68.2% female; mean [SD] age, 75.4 [8.8] years), 7145 non-Hispanic Black (hereafter referred to as Black) (70.8% female; mean [SD] age, 78.4 [8.2] years), and 34 021 non-Hispanic White (hereafter referred to as White) (59.3% female; mean [SD] age, 77.0 [9.1] years) individuals. +4 more findings

    Full summary, score breakdown and related studies → Original source

  8. 2023-12-01

    Association Between Slow-Wave Sleep Loss and Incident Dementia

    ✓ Peer-reviewed Prevention and risk JAMA Neurology

    Key finding: From the 868 Framingham Heart Study participants who returned for a second PSG, this cohort included 346 participants with a mean age of 69 years (range, 60-87 years); 179 (52%) were female. +3 more findings

    Full summary, score breakdown and related studies → Original source

November 2023 17

  1. 2023-11-30

    Late-life food insecurity and cognition: exploring timing, duration, and mechanisms among older Mexican adults

    ✓ Peer-reviewed Risk factors BMC Geriatrics

    Key finding: Approximately half of the sample were persistently food secure, 17% became food secure, 14% became FI, and 15% experienced persistent FI. +4 more findings

    Full summary, score breakdown and related studies → Original source

  2. 2023-11-29

    INPP5D regulates inflammasome activation in human microglia

    ✓ Peer-reviewed Inflammation and the immune system Nature communications

    Key finding: Inositol polyphosphate-5-phosphatase D (INPP5D/SHIP1) is a myeloid-expressed gene genetically-associated with AD. +4 more findings

    Full summary, score breakdown and related studies → Original source

  3. 2023-11-29

    Alzheimer's Related Neurodegeneration Mediates Air Pollution Effects on Medial Temporal Lobe Atrophy

    ⚠ Preprint — not yet peer-reviewed Risk factors medRxiv : the preprint server for health sciences

    Key finding: Living in locations with higher PM2.5 (per interquartile range [IQR]=3.17μg/m3) or NO2 (per IQR=6.63ppb) was associated with greater MTL atrophy (βPM2.5 = -0.29, 95% confidence interval [CI]=[-0.41,-0.18]; βNO2 =-0.12, 95%CI=[-0.23,-0.02]). +4 more findings

    Scored 43 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

    Full summary, score breakdown and related studies → Original source

  4. 2023-11-29

    Genome-wide association study in Alzheimer's disease: a bibliometric and visualization analysis

    ✓ Peer-reviewed Genetics Frontiers in aging neuroscience

    Key finding: A total of 1,350 publications with 59,818 citations were identified. +4 more findings

    Full summary, score breakdown and related studies → Original source

  5. 2023-11-29

    The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders

    ✓ Peer-reviewed Risk factors Cells

    Key finding: These models have also revealed the impact of various stressors, including social hierarchies, highlighting the role of social factors in cortisol regulation. +1 more finding

    Full summary, score breakdown and related studies → Original source

  6. 2023-11-29

    Cerebral Small Vessel Disease, Hypertension, and Vascular Contributions to Cognitive Impairment and Dementia

    ✓ Peer-reviewed Brain tissue and pathology Hypertension (Dallas, Tex. : 1979)

    Key finding: Strongly associated with age and hypertension, small vessel disease is found at autopsy in over 50% of people aged ≥65 years, with a spectrum of clinical manifestations. +3 more findings

    Full summary, score breakdown and related studies → Original source

  7. 2023-11-29

    Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer's disease

    ✓ Peer-reviewed TREM2 and immune genetics Molecular neurodegeneration

    Key finding: Several of these genes have been recognized for their central roles in microglial functions. +3 more findings

    Full summary, score breakdown and related studies → Original source

  8. 2023-11-29

    Cerebrovascular disease drives Alzheimer plasma biomarker concentrations in adults with Down syndrome

    ⚠ Preprint — not yet peer-reviewed Down syndrome and Alzheimer's medRxiv

    Key finding: By age 40 years over 90% of adults with Down syndrome (DS) have Alzheimer’s disease (AD) pathology and most progress to dementia. +3 more findings

    Scored 30 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

    Full summary, score breakdown and related studies → Original source

  9. 2023-11-28

    The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials

    ✓ Peer-reviewed Biomarkers European journal of medical research

    Key finding: FDA-approved anti-Aβ mabs have a role in slowing disease progression in patients with AD, at the cost of an increased probability of side effects. +2 more findings

    Full summary, score breakdown and related studies → Original source

  10. 2023-11-28

    Plasma proteomic profiles predict individual future health risk

    ✓ Peer-reviewed Prevention and risk Nature communications

    Key finding: Incorporating clinical predictors with ProRS enhanced predictive power for most endpoints, but this combination only exhibited limited improvement when compared to ProRS alone. +3 more findings

    Full summary, score breakdown and related studies → Original source

  11. 2023-11-28

    Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants

    ✓ Peer-reviewed Genetics Molecular Neurodegeneration

    Key finding: 37 heterozygous carriers (27 female, 10 male) identified from whole-exome (n = 454,756) and whole-genome (n = 141,948) sequencing; allele frequency 0.004% +3 more findings

    Full summary, score breakdown and related studies → Original source

  12. 2023-11-27

    Implementing Dementia Caregiver Programs in Real-World Settings: Fidelity Considerations

    ✓ Peer-reviewed Caregiving Journal of the American Medical Directors Association

    Key finding: Additionally, 7 (63.6%) of 11 studies reported fidelity results, representing only 22.5% of 31 studies reporting outcomes demonstrating the inconsistency in the field concerning the reporting outcomes of fidelity. +1 more finding

    Full summary, score breakdown and related studies → Original source

  13. 2023-11-27

    Mutant-Huntingtin Molecular Pathways Elucidate New Targets for Drug Repurposing

    ✓ Peer-reviewed Drug development International journal of molecular sciences

    Key finding: This disorder is known to result from a mutation in the HTT gene, but having this information still does not simplify the task of drug development and studying the mechanisms of disease progression.

    Full summary, score breakdown and related studies → Original source

  14. 2023-11-27

    Resting-state global brain activity affects early β-amyloid accumulation in default mode network

    ✓ Peer-reviewed Brain scans and imaging Nature communications

    Key finding: Here we show that the preferential Aβ accumulation in the DMN at the early stage of Aβ pathology was associated with the preferential reduction of global brain activity in the same regions. +1 more finding

    Full summary, score breakdown and related studies → Original source

  15. 2023-11-27

    Brain apolipoprotein E levels in mice challenged by a Western diet increase in an allele-dependent manner

    ✓ Peer-reviewed Genetics Aging brain

    Key finding: While APOE4 drives memory loss and high AD risk, APOE2 leads to healthy brain aging and reduced AD risk compared to the common APOE3 variant.

    Full summary, score breakdown and related studies → Original source

  16. 2023-11-27

    Remote and in-clinic digital cognitive screening tools outperform the MoCA to distinguish cerebral amyloid status among cognitively healthy older adults

    ✓ Peer-reviewed Cognitive tests and assessment Alzheimer's & dementia (Amsterdam, Netherlands)

    Key finding: Average performance on the episodic memory (Prices) smartphone task showed the highest accuracy (AUC = 0.77) to distinguish Aβ status. +2 more findings

    Full summary, score breakdown and related studies → Original source

  17. 2023-11-27

    TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease

    ✓ Peer-reviewed Drug development Nature aging

    Key finding: Here, we report the results of TANGO ( NCT03352557 ), a randomized, double-blind, placebo-controlled, parallel-group and multiple-dose long-term trial of gosuranemab-a monoclonal antibody to N-terminal tau-in patients with early Alzheimer's disease. +3 more findings

    Full summary, score breakdown and related studies → Original source

Browse the library by subject, with the full score breakdown →